通心络胶囊辅助治疗冠心病心血管终点事件的系统评价与Meta分析
结果显示通心络可降低心肌梗死、靶血管血运重建或支架内再狭窄、脑血管意外、心力衰竭及心血管病非计划再入院风险,但心血管死亡无显著关联,不良反应轻微。
要点
- 通心络辅助治疗可降低冠心病患者心肌梗死和靶血管血运重建或支架内再狭窄风险。
- 通心络可能降低脑血管意外、心力衰竭及心血管病非计划再入院风险。
- 通心络对心血管死亡的影响因样本量不足未能确认,不良反应轻微。
核心结论
- 通心络胶囊辅助治疗对预防冠心病患者心血管不良事件有益,尤其是血运重建术后靶血管再狭窄。
- 通心络可能降低12个月内首发或复发心肌梗死及心力衰竭发生率,但样本量不足提示结果稳定性有限。
- 通心络对心血管死亡、脑血管事件及心血管病非计划再入院的影响因病例数不足未能确认。
研究设计与样本
- 系统评价与Meta分析,检索Pubmed、Cochrane Library、CNKI、VIP、万方及CBM自建库至2020年3月。
- 主要终点为心肌梗死、靶血管血运重建或支架内再狭窄及心血管死亡,并采用试验序贯分析减少随机误差。
主要发现
- 与安慰剂相比,通心络降低心肌梗死风险(RR=0.44,95%CI 0.24-0.80)。
- 通心络降低靶血管血运重建或支架内再狭窄风险(RR=0.43,95%CI 0.31-0.58)。
- 通心络降低脑血管意外风险(RR=0.17,95%CI 0.06-0.46)和心力衰竭风险(RR=0.41,95%CI 0.21-0.79)。
- 通心络降低心血管病非计划再入院风险(RR=0.72,95%CI,P=0.04),但与心血管死亡无显著关联(RR=0.53,95%CI 0.15-1.91)。
- 不良反应轻微,通心络组与安慰剂组无显著差异。
关键数值与推荐
- 2个月亚组:心肌梗死RR=0.44(95%CI 0.13-1.53),心血管死亡RR=0.30(95%CI 0.01-7.67),脑血管意外RR=0.04(95%CI 0.01-0.26),非计划再入院RR=0.43(95%CI 0.20-0.94)。
- 12个月亚组:心肌梗死RR=0.42(95%CI 0.20-0.89),靶血管血运重建或支架内再狭窄RR=0.42(95%CI 0.31-0.58),心力衰竭RR=0.34(95%CI 0.14-0.78),非计划再入院RR=0.85(95%CI 0.59-1.22)。
临床怎么用
- 对于冠心病患者,可考虑在常规治疗基础上辅助使用通心络胶囊以降低心肌梗死及血运重建后靶血管再狭窄风险。
- 使用通心络辅助治疗时需关注其对脑血管意外、心力衰竭及非计划再入院的潜在获益,但心血管死亡获益不明确。
- 临床决策应结合患者个体情况,并注意现有证据样本量有限、随访时间较短的局限性。
局限性
- 纳入研究样本量不足,提示部分结果稳定性有限。
- 心血管死亡、脑血管事件及非计划再入院等终点因病例数不足未能确认。
- 治疗时长2至12个月不等,长期疗效需更大样本和延长随访的试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Tongxinluo Capsule(TXLC) is a well-known traditional Chinese medicine prescription with effects of tonifying Qi and activating blood based on the Chinese herbal medicine theory that has been recommended as routine adjuvant treatment in patients with coronary heart disease (CHD) in China. AIM OF THE STUDY: This meta-analysis aimed to evaluate the efficacy and safety of TXLC as supplementation in the prevention of adverse cardiovascular events in patients with CHD. MATERIALS AND METHODS: We performed a literature search in Pubmed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wan Fang Database, and Chinese Biomedical Database (CBM) from their inceptions to March 2020. Only randomized controlled trials (RCTs) that assessed supplementation with TXLC or placebo and with adverse cardiovascular outcomes, were included in this meta-analysis. Primary end points were myocardial infarction (MI), target vessel revascularization (TVR) or in-stent restenosis (ISR), and cardiovascular death. Secondary end points included cerebrovascular accidents, heart failure (HF), and unscheduled readmission for cardiovascular diseases (CVDs). Adverse drug events were also evaluated. Trial sequential analysis (TSA) was conducted to reduce random errors introduced by possible insufficient sample size. RESULTS: Eleven RCTs involving 1505 patients were analyzed. The mean(SD) age of included patients were 59.03(9.7) years. Treatment duration varied from 2 months to 12 months. Compared with placebo, TXLC supplementation showed significant effects on reducing the risk of MI (RR = 0.44, [95% CI, 0.24-0.80]), TVR or ISR (RR = 0.43, [95% CI, 0.31-0.58]), cerebrovascular accidents(RR = 0.17, [95% CI, 0.06-0.46]), HF (RR = 0.41, [95% CI, 0.21-0.79]), and unscheduled readmission for CVDs (RR = 0.72, [95% CI], P = 0.04), but did not have associations with incidence of cardiovascular death (RR = 0.53, [95% CI, 0.15-1.91]). Subgroups of trials with 2-month (MI: RR = 0.44, [95% CI, 0.13-1.53]; cardiovascular death: RR = 0.30, [95% CI, 0.01-7.67]; cerebrovascular accidents: RR = 0.04, [95% CI, 0.01-0.26]; unscheduled readmission for CVDs: RR = 0.43, [95% CI, 0.20-0.94]) and 12-month (MI: RR = 0.42, [95% CI, 0.20-0.89]; TVR or ISR: RR = 0.42, [95% CI, 0.31-0.58]; HF: RR = 0.34, [95% CI, 0.14-0.78]; unscheduled readmission for CVDs: RR = 0.85, [95% CI, 0.59-1.22]) intervention period were analyzed. The adverse drug reactions were mild with no significant difference between TXLC and placebo. CONCLUSIONS: This meta-analysis indicated that TXLC supplementation had beneficial effects on the prevention of cardiovascular adverse events, especially in TVR or ISR after coronary revascularization and may possibly lower the incidence of first or recurrent MI and HF within 12 months in patients with CHD, while insufficient sample size implied that these results lacked certain stability. And the effects of TXLC on cardiovascular mortality, cerebrovascular events, and unscheduled readmission for CVDs could not be confirmed due to insufficient cases. Clinical trials with large-sample sizes and extended follow-up time are of interest in the future researches.
引用
- Lv J, Liu S, Guo S, et al. Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Ethnopharmacol. 2022. PMID: 35091010. doi:10.1016/j.jep.2022.115033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。